文献速递眼底病与葡萄膜炎神经眼科角膜与眼表疾病

眼科免疫相关不良事件与生存期的关联:来自真实世界数据库的结果

Ophthalmic Immune-Related Adverse Events and Association with Survival: Results From a Real-World Database.
PubMed 文献 · Am J Ophthalmol · 2024-09-11

这项回顾性队列研究利用TriNetX电子健康记录数据库,纳入41,020例接受免疫检查点抑制剂(ICI)治疗的患者,分析眼科免疫相关不良事件(irAEs)的发生率及其与总生存期的关联。结果显示干眼综合征最常见(2%),前节irAEs较后节更常见;12个月界标分析中,任何眼科irAE(HR 1.37)、神经眼科irAE(HR 1.53)和角膜与眼表irAE(HR 1.34)与生存期显著缩短相关。

要点

  • 最常见眼科irAEs为干眼综合征(2%)、结膜炎(0.87%)、睑缘炎(0.51%)、前葡萄膜炎(0.39%)和角膜炎(0.38%)。
  • CTLA-4抑制剂联合PD-1抑制剂和前葡萄膜炎发生率(1.39%和1.29%)高于PD-1抑制剂(0.27%)和PD-L1抑制剂(0.14%)。
  • 12个月界标分析中,任何眼科irAE(HR 1.37)、神经眼科irAE(HR 1.53)和角膜与眼表irAE(HR 1.34)与生存期显著缩短相关。

核心结论

  • 累及前节的眼科irAEs较后节更常见,且与ICI类别无关。
  • 眼科irAEs可能预示生存期缩短。
  • 这一认识可帮助指导临床医生积极管理irAEs,并使患者尽管存在眼部问题仍能继续ICI治疗。

研究设计与样本

  • 回顾性队列研究,数据来自TriNetX电子健康记录数据库。
  • 纳入首次ICI治疗后1年内发生眼科irAEs的患者,排除ICI治疗前6个月内有明确眼部毒性者。
  • 采用倾向评分匹配对照,匹配变量为人口学特征和癌症类型。
  • 使用Cox比例风险模型确定风险比,Kaplan-Meier生存函数以log-rank检验评估,基于12个月界标分析中眼科irAEs的发生情况。

主要发现

  • 队列共41,020例患者,男性占57.4%,平均年龄65.2±11.9岁。
  • 最常见的5种眼科irAEs为干眼综合征(2%)、结膜炎(0.87%)、睑缘炎(0.51%)、前葡萄膜炎(0.39%)和角膜炎(0.38%)。
  • 干眼综合征是所有ICI类别中最常见的irAE。
  • 使用CTLA-4抑制剂联合PD-1抑制剂和CTLA-4抑制剂者,前葡萄膜炎发生率分别为1.39%和1.29%,高于PD-1抑制剂(0.27%)和PD-L1抑制剂(0.14%)。
  • 12个月界标分析后,以下类别生存机会显著降低:任何眼科irAE(HR 1.37;95%CI 1.20-1.56;P<.0001)、神经眼科irAE(HR 1.53;95%CI 1.09-2.14;P=.0124)、角膜与眼表irAE(HR 1.34;95%CI 1.15-1.56;P<.0001)。

关键数值与推荐

  • 眼科irAEs定义为首次ICI治疗后1年内发生,且排除ICI治疗前6个月内有明确眼部毒性者。
  • 倾向评分匹配基于人口学特征和癌症类型。
  • 12个月界标分析用于评估眼科irAEs发生后的生存情况。

临床怎么用

  • 作者认为,这一认识可帮助指导临床医生积极管理irAEs,并使患者尽管存在眼部问题仍能继续ICI治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Assessing immune-related ocular toxicities from immune checkpoint inhibitors (ICIs) is crucial, though rare. This study, utilizing real-world data, examines the occurrence of ophthalmic immune-related adverse events (irAEs) after ICI treatment and their impact on overall survival. DESIGN: A retrospective cohort study. METHODS: Data were obtained from TriNetX, an aggregated electronic health records database. Patients who developed ophthalmic irAEs within 1 year after the first instance of ICI therapy were included. Participants with defined ocular toxicities 6 months before ICI treatment were excluded. Subjects were paired with controls using propensity scores derived from demographics and cancer type. A Cox proportional hazard model was used to determine hazard ratios. A Kaplan-Meier survival function was evaluated with the log-rank test based on the development of ophthalmic irAEs in a 12-month landmark analysis. RESULTS: A cohort of 41,020 patients comprising 57.4% males with a mean age of 65.2 ± 11.9 years was included. The 5 most prevalent ophthalmic irAEs in this cohort were dry eye syndrome (2%), conjunctivitis (0.87%), blepharitis (0.51%), anterior uveitis (0.39%), and keratitis (0.38%). Dry eye syndrome was the most common irAE among all ICI classes. Subjects taking CTLA-4 inhibitor plus PD-1 inhibitor and CTLA-4 inhibitors had higher rates of anterior uveitis (1.39% and 1.29%, respectively) than PD-1 inhibitors (0.27%) and PD-L1 inhibitors (0.14%) within 1 year after taking ICI. After a 12-month landmark analysis, there was a significant decreased chance of survival for the following categories: any ophthalmic irAE (HR, 1.37; 95% CI, 1.20-1.56; P < .0001), neuro-ophthalmic irAE (HR, 1.53; 95% CI, 1.09-2.14; P = .0124), and cornea and ocular surface irAE (HR, 1.34; 95% CI, 1.15-1.56; P < .0001). CONCLUSIONS: Ophthalmic irAEs involving the anterior segment are more frequent than the posterior segment, regardless of ICI class. Ophthalmic irAEs may also portend decreased survival. This insight could help guide clinicians aggressively manage irAEs and allow patients to continue ICI therapy despite having ocular issues.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Quiruz L, Yavari N, Kikani B, et al. Ophthalmic Immune-Related Adverse Events and Association with Survival: Results From a Real-World Database. Am J Ophthalmol. 2024. PMID: 39271090. doi:10.1016/j.ajo.2024.08.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。